Complement activation (WP545)
Homo sapiens
The complement system is a biochemical cascade that helps, or complements, the ability of antibodies to clear pathogens from an organism. It is part of the immune system called the innate immune system that is not adaptable and does not change over the course of an individual's lifetime. However, it can be recruited and brought into action by the adaptive immune system. The classical pathway of activation of the complement system is a group of blood proteins that mediate the specific antibody response. [source: Wikipedia] The classical pathway begins with circulating C1Q binding to an antigen on the surface of a pathogen, which goes on to active and recruit 2 copies of each C1R and C1S, forming a C1 complex. The activated C1 complex cleaves C2 and C4. Activated cleavage products C2A and C4B combine to form C3 convertase, which cleaves C3. The cleavage product C3B joins the complex to form C5 convertase, which cleaves C5. The cleavage product C5B joins C6, C7, C8 and multiple copies of C9 to form the membrane attack complex, which forms a channel for water to flood into the target cell, leading to osmotic lysis. The decay accelerating factor (DAF) inhibits C3 convertase. The lectin pathway involves mannose-binding lectin (MBL) binding the surface of the pathogen instead of C1Q. MBL-associated serine proteases MASP1 and MASP1 can cleave C2 and C4 in place of the C1 complex, leading to the formation of C3 convertase and the subsequent cascade. The alternative pathway relies on the spontaneous hydrolysis of C3 and the cleavage of factor B (CFB) by factor D (CFD), which form an alternative C3 convertase stabilized by factor P (CFP). Additional copies of the cleavage product C3B are recruited to the complex, resulting in an alternative C5 convertase, which cleaves C5 and contributes C5B to the formation of the membrane attack complex. Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP545 CPTAC Assay Portal]
Authors
Nathan Salomonis , Kristina Hanspers , Michiel Adriaens , Christine Chichester , Martina Summer-Kutmon , Alex Pico , Egon Willighagen , and Eric WeitzActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
- Cell invasion in digital microfluidic microgel systems (2020).
- A proteomic signature that reflects pancreatic beta-cell function (2018).
- Long Term Culture of the A549 Cancer Cell Line Promotes Multilamellar Body Formation and Differentiation towards an Alveolar Type II Pneumocyte Phenotype (2016).
- Discovering Common Pathogenic Mechanisms of COVID-19 and Parkinson Disease: An Integrated Bioinformatics Analysis (2022).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
Annotations
Pathway Ontology
classical complement pathwayLabel | Type | Compact URI | Comment |
---|---|---|---|
H2O | Metabolite | hmdb:HMDB0002111 | |
C1S | GeneProduct | ncbigene:716 | |
C1QB | GeneProduct | ncbigene:713 | |
C1R | GeneProduct | ensembl:ENSG00000159403 | |
C1QA | GeneProduct | ncbigene:712 | update: C1QA HUMAN |
C1QG | GeneProduct | ncbigene:714 | update C1QC HUMAN |
C8A | GeneProduct | ncbigene:731 | |
MASP2 | GeneProduct | ncbigene:10747 | |
C2A | GeneProduct | ncbigene:717 | |
C3 | GeneProduct | ncbigene:718 | |
C9 | GeneProduct | ncbigene:735 | |
C8B | GeneProduct | ncbigene:732 | |
C6 | GeneProduct | ncbigene:729 | |
C4B | GeneProduct | ncbigene:721 | |
DAF | GeneProduct | ncbigene:1604 | |
C4A | GeneProduct | ncbigene:720 | |
C7 | GeneProduct | ncbigene:730 | |
C5 | GeneProduct | ncbigene:727 | |
C2 | GeneProduct | ncbigene:717 | |
C3B | GeneProduct | ncbigene:718 | |
C5B | GeneProduct | ncbigene:727 | |
C8G | GeneProduct | ncbigene:733 | |
MASP1 | GeneProduct | ncbigene:5648 | |
CFBb | GeneProduct | ncbigene:629 | |
CFB | GeneProduct | ncbigene:629 | |
CFD | GeneProduct | ncbigene:1675 | |
CFP | GeneProduct | ncbigene:5199 |
References
- Opportunities for new therapies based on the natural regulators of complement activation. Brook E, Herbert AP, Jenkins HT, Soares DC, Barlow PN. Ann N Y Acad Sci. 2005 Nov;1056:176–88. PubMed Europe PMC Scholia